Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis

Abstract Objectives We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA. Methods Of 64 patients with PsA resistant to MTX, 26 underwent bDMARDs therapy selected according to phenotypic differences in peripheral...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2019-02, Vol.58 (2), p.336-344
Main Authors: Miyagawa, Ippei, Nakayamada, Shingo, Nakano, Kazuhisa, Kubo, Satoshi, Iwata, Shigeru, Miyazaki, Yusuke, Yoshikawa, Maiko, Yoshinari, Hiroko, Tanaka, Yoshiya
Format: Article
Language:English
Subjects:
Arthritis
CCR6 protein
CD38 antigen
CXCR3 protein
Flow cytometry
Helper cells
Histocompatibility antigen HLA
Lymphocytes T
Monoclonal antibodies
Peripheral blood
Phenotypes
Precision medicine
Psoriasis
Psoriatic arthritis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives We sought to investigate the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating PsA. Methods Of 64 patients with PsA resistant to MTX, 26 underwent bDMARDs therapy selected according to phenotypic differences in peripheral helper T cells on 8-colour flow cytometry. The efficacies of this strategic treatment and the standard treatment administered to the other 38 patients were evaluated at 6 months. Results The 26 patients with PsA in the strategic treatment group were classified into the following four types based on peripheral blood analysis: (i) CXCR3+CCR6−CD38+HLA-DR+ activated Th1 cell-predominant type, (ii) CXCR3−CCR6+ CD38+HLA-DR+ activated Th17 cell-predominant type, (iii) Th1/Th17-high type and (iv) Th1/Th17-low type. Accordingly, ustekinumab was administered to the activated Th1 cell-predominant patients, secukinumab to the activated Th17 cell-predominant patients, secukinumab or TNF inhibitor to the Th1/Th17-high patients, and TNF inhibitor to the Th1/Th17-low patients. After 6 months of strategic treatment, there was a significant decrease in simplified disease activity index (SDAI) (from 16.2 to 3.52), DAS28 (ESR) (from 4.13 to 2.27) and psoriasis area and severity index (from 8.36 to 2.40). Low disease activity by SDAI was achieved in 24 (92.3%) of the 26 patients. The rate of low disease activity achievement according to SDAI at 6 months was significantly higher in the strategic bDMARDs treatment group compared with that of the standard bDMARDs treatment group. Conclusion Strategic treatment in which different bDMARDs were selected according to phenotypic differences in helper T cells showed significantly higher efficacy than standard bDMARD therapy, indicating the value of precision medicine.
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/key069